Treatment-Resistant Depression Therapies
Treatment-Resistant Depression Market

Treatment-Resistant Depression 


Treatment-resistant Depression (TRD) typically refers to inadequate response to at least one antidepressant trial of adequate doses and duration. Treatment-resistant Depression is a relatively common occurrence in clinical practice, with up to 50–60% of the patients not achieving adequate response following antidepressant treatment.


Treatment-Resistant Depression Epidemiology Segmentation in the 7MM 


  • Total Diagnosed Prevalent Cases Treatment-Resistant Depression
  • Age-Specific Cases of Treatment-Resistant Depression
  • Gender-specific Cases of Treatment-Resistant Depression


Treatment-Resistant Depression Epidemiological Insights Observed in the 7MM (2021)


  • The total prevalent cases of Treatment-Resistant Depression in the 7MM were estimated to be 5.8 million.
  • The total prevalent cases of Treatment-Resistant Depression in the US were estimated to be 3.9 million.
  • The total prevalent cases of Treatment-Resistant Depression in Germany was found to be  558k and in Italy, they were found to be 127k in the year 2021.


Treatment-Resistant Depression Market Insight


The market size of Treatment-Resistant Depression in the 7MM was found to be USD 2,450 million in 2021.

 

Treatment-Resistant Depression Emerging Therapies


The emerging drugs in the Treatment-Resistant Depression market are


  • AXS-05
  • VRAYLAR
  • Esketamine DPI
  • REL-1017
  • COMP360
  • MIJ821
  • Liafensine
  • MK-1942
  • NV5138
  • TS161
  • AV-101, and many others


Treatment-Resistant Depression Key Players 


The key players working in the Treatment-Resistant Depression market are


  • Axsome Therapeutics
  • AbbVie
  • Celon Pharma
  • Relmada Therapeutics
  • COMPASS Pathways
  • Novartis
  • Denovo Biopharma
  • Merck Sharp and Dohme Corp
  • Navitor Pharmaceuticals, Inc.
  • Supernus Pharmaceuticals, Inc.
  • Taisho Pharmaceutical Co., Ltd
  • VistaGen Therapeutics, and several others